Varrone A, Marek K L, Jennings D, Innis R B, Seibyl J P
Department of Diagnostic Radiology, Yale University School of Medicine, New Haven, Connecticut, USA.
Mov Disord. 2001 Nov;16(6):1023-32. doi: 10.1002/mds.1256.
In vivo imaging of the dopamine transporter (DAT) with single photon emission computed tomography (SPECT) is a quantitative biomarker for Parkinson's disease (PD) onset and severity. This study has examined and compared the loss of striatal DAT in PD and multiple system atrophy (MSA) using [(123)I]beta-CIT SPECT imaging. One hundred and eighty-three patients (157 PD and 26 MSA) were studied. Clinical rating scales (Hoehn and Yahr stage and Unified Parkinson's Disease Rating Scale [UPDRS] scores) demonstrated that the MSA patients were more severely impaired than the PD patients. The striatal [(123)I]beta-CIT SPECT uptake was markedly reduced in both the PD and MSA groups. In addition, MSA patients showed more symmetric DAT loss compared with the PD patients, consistent with the more symmetric clinical motor dysfunction observed in MSA. While the loss of DAT was significantly reduced in all regions in both MSA and PD, comparison of the relative loss of the DAT did not significantly improve diagnostic accuracy in distinguishing between PD and MSA.
利用单光子发射计算机断层扫描（SPECT）对多巴胺转运体（DAT）进行体内成像，是帕金森病（PD）发病及严重程度的一种定量生物标志物。本研究使用[（123）I]β-CIT SPECT成像检查并比较了PD和多系统萎缩（MSA）患者纹状体DAT的缺失情况。共研究了183例患者（157例PD患者和26例MSA患者）。临床评定量表（Hoehn和Yahr分期以及统一帕金森病评定量表[UPDRS]评分）显示，MSA患者的受损程度比PD患者更严重。PD组和MSA组的纹状体[（123）I]β-CIT SPECT摄取均明显降低。此外，与PD患者相比，MSA患者的DAT缺失更对称，这与MSA中观察到的更对称的临床运动功能障碍一致。虽然MSA和PD患者所有区域的DAT缺失均显著降低，但比较DAT的相对缺失并未显著提高区分PD和MSA的诊断准确性。
